Reduced muscle carnosine content in type 2, but not in type 1 diabetic patients

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author GUALANO, Bruno
EVERAERT, Inge
STEGEN, Sanne
ARTIOLI, Guilherme Giannini
TAES, Youri
ROSCHEL, Hamilton
ACHTEN, Eric
OTADUY, Maria Concepcion FMUSP-HC
LANCHA JUNIOR, Antonio Herbert
HARRIS, Roger
DERAVE, Wim
dc.date.issued 2012
dc.identifier.citation AMINO ACIDS, v.43, n.1, p.21-24, 2012
dc.identifier.issn 0939-4451
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/1576
dc.description.abstract Carnosine is present in high concentrations in skeletal muscle where it contributes to acid buffering and functions also as a natural protector against oxidative and carbonyl stress. Animal studies have shown an anti-diabetic effect of carnosine supplementation. High carnosinase activity, the carnosine degrading enzyme in serum, is a risk factor for diabetic complications in humans. The aim of the present study was to compare the muscle carnosine concentration in diabetic subjects to the level in non-diabetics. Type 1 and 2 diabetic patients and matched healthy controls (total n = 58) were included in the study. Muscle carnosine content was evaluated by proton magnetic resonance spectroscopy (3 Tesla) in soleus and gastrocnemius. Significantly lower carnosine content (-45%) in gastrocnemius muscle, but not in soleus, was shown in type 2 diabetic patients compared with controls. No differences were observed in type 1 diabetic patients. Type II diabetic patients display a reduced muscular carnosine content. A reduction in muscle carnosine concentration may be partially associated with defective mechanisms against oxidative, glycative and carbonyl stress in muscle.
dc.description.sponsorship · Research Foundation-Flanders (FWO) [1.5.149.08, G.0046.09]
· Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2005/56464-9, 2010/11221-0]
dc.language.iso eng
dc.publisher SPRINGER
dc.relation.ispartof Amino Acids
dc.rights restrictedAccess
dc.subject Skeletal muscle; Glycation; AGEs; Oxidative stress; Carbonyl stress; Carnosine; Beta-alanine; Diabetic complications; MRS
dc.subject.other beta-alanine supplementation; human skeletal-muscle; vastus lateralis; metabolism; exercise; taurine; cells
dc.title Reduced muscle carnosine content in type 2, but not in type 1 diabetic patients
dc.type article
dc.rights.holder Copyright SPRINGER
dc.description.group LIM/44
dc.identifier.doi 10.1007/s00726-011-1165-y
dc.identifier.pmid 22120670
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author OTADUY, Maria Concepcion:HC:INRAD
hcfmusp.author.external · GUALANO, Bruno:Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam Human Movement, BR-05508030 Sao Paulo, Brazil
· EVERAERT, Inge:Univ Ghent, Dept Movement & Sports Sci, B-9000 Ghent, Belgium
· STEGEN, Sanne:Univ Ghent, Dept Movement & Sports Sci, B-9000 Ghent, Belgium
· ARTIOLI, Guilherme Giannini:Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam Human Movement, BR-05508030 Sao Paulo, Brazil
· TAES, Youri:Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium
· ROSCHEL, Hamilton:Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam Human Movement, BR-05508030 Sao Paulo, Brazil
· ACHTEN, Eric:Univ Ghent, Dept Radiol & Nucl Med, Ghent Inst Funct & Metab Imaging GIfMI, B-9000 Ghent, Belgium
· LANCHA JUNIOR, Antonio Herbert:Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam Human Movement, BR-05508030 Sao Paulo, Brazil
· HARRIS, Roger:Univ Sao Paulo, Sch Phys Educ & Sports, Dept Biodynam Human Movement, BR-05508030 Sao Paulo, Brazil
· DERAVE, Wim:Univ Ghent, Dept Movement & Sports Sci, B-9000 Ghent, Belgium
hcfmusp.origem.id WOS:000305210800004
hcfmusp.origem.id 2-s2.0-84862765242
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Aldini G, 2011, J CELL MOL MED, V15, P1339, DOI 10.1111/j.1582-4934.2010.01101.x
· Artioli GG, 2010, MED SCI SPORT EXER, V42, P1162, DOI 10.1249/MSS.0b013e3181c74e38
· Baguet A, 2009, J APPL PHYSIOL, V106, P837, DOI 10.1152/japplphysiol.91357.2008
· BAKARDJIEV A, 1994, EUR J BIOCHEM, V225, P617, DOI 10.1111/j.1432-1033.1994.00617.x
· Boldyrev A.A., 2006, CARNOSINE OXIDATIVE
· BUSE MG, 1980, METABOLISM, V29, P605, DOI 10.1016/0026-0495(80)90104-3
· Derave W, 2010, SPORTS MED, V40, P247, DOI 10.2165/11530310-000000000-00000
· Harris RC, 2006, AMINO ACIDS, V30, P279, DOI 10.1007/s00726-006-0299-9
· Janssen B, 2005, DIABETES, V54, P2320, DOI 10.2337/diabetes.54.8.2320
· Kim HJ, 2009, AMINO ACIDS, V36, P359, DOI 10.1007/s00726-008-0092-z
· Lee YT, 2005, EUR J PHARMACOL, V513, P145, DOI 10.1016/j.ejphar.2005.02.010
· Mooyaart AL, 2010, DIABETOLOGIA, V54, P544
· Oberbach A, 2006, DIABETES CARE, V29, P895, DOI 10.2337/diacare.29.04.06.dc05-1854
· Pfister F, 2011, CELL PHYSIOL BIOCHEM, V28, P125, DOI 10.1159/000331721
· Riedl E, 2011, CELL PHYSIOL BIOCHEM, V28, P279, DOI 10.1159/000331740
· Sale C, 2010, AMINO ACIDS, V39, P321, DOI 10.1007/s00726-009-0443-4
· Sauerhofer S, 2007, DIABETES, V56, P2425, DOI 10.2337/db07-0177
· Stephens FB, 2006, FASEB J, V20, P377, DOI 10.1096/fj.05-4985fje
· Tallon MJ, 2007, BIOGERONTOLOGY, V8, P129, DOI 10.1007/s10522-006-9038-6
dc.description.index MEDLINE
hcfmusp.citation.scopus 25
hcfmusp.citation.wos 23
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Bélgica


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics